Guerbet : CA T3 2024 – Inférieur à nos attentes– Guidance confirmée
>CA T3 2024 : +3,1% - Le CA T3 s’élève à 201,3 M€, soit + 3,1% (+5,4% à tcc.). Sur 9 mois, le CA ressort à 620,5 M€ (+8,1% et +9,6% à tcc). Par zone, sur 9 mois l’EMEA affiche une croissance de +1,2% (+1,0% à tcc.), l’APAC est en hausse de 6,6% (+10,3% à tcc.) et les Amériques sont en croissance de 20,7% (+22,9% à tcc.). Par segment, les Rayons-X affichent +11,2% (+13,1% à tcc.), l’IRM est en croissance de +2,4% (+3,1% à tcc.) et la RIT +9,9% (+11,3% à tcc.).Le m...Guerbet is a French pharmaceutical group that develops, markets, and provides maintenance services for medical equipment and devices destined for diagnostic and interventional imaging. Co.'s portfolio comprises media solutions covering MRI, X-rays and products devoted to International Radiology and Theranostics and medical devices. Co. organizes its operation by product family covering Magnetic Resonance Imaging (MRI), X-rays (XR) and Interventional Radiology and Theranostics (IRT). The MRI family includes Dotarem® and Artirem®; Co.'s X-ray product family includes Xenetix®, Optiray®/Optiject®, Oxilan®, and Telebrix®; and the IRT product family has Lipiodol®, Bleu Patente V and Hexabrix®.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.